What is Elevation Oncology Profitability Rank?
Elevation Oncology has the Profitability Rank of 1. It has had trouble to make a profit.
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:
1.
Operating Margin %
2.
Piotroski F-Score
3. Trend of the
Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Elevation Oncology's Operating Margin % for the quarter that ended in Mar. 2024 was %. As of today, Elevation Oncology's Piotroski F-Score is 2.
Competitive Comparison of Elevation Oncology's Profitability Rank
For the Biotechnology subindustry, Elevation Oncology's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Elevation Oncology's Profitability Rank Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Elevation Oncology's Profitability Rank distribution charts can be found below:
* The bar in red indicates where Elevation Oncology's Profitability Rank falls into.
Elevation Oncology Profitability Rank Calculation
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.
The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.
Elevation Oncology has the Profitability Rank of 1. It has had trouble to make a profit.
Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.
Profitability Rank is based on these factors:
1. Operating Margin %
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Elevation Oncology's Operating Margin % for the quarter that ended in Mar. 2024 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
2. Piotroski F-Score
Warning Sign:
Piotroski F-Score of 2 is low, which usually implies poor business operation.
The zones of discrimination were as such:
Good or high score = 8 or 9
Bad or low score = 0 or 1
Elevation Oncology has an F-score of 2. It is a bad or low score, which usually implies poor business operation.
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank
Elevation Oncology (Elevation Oncology) Business Description
Traded in Other Exchanges
N/A
Address
888 Seventh Avenue, 12th Floor, New York, NY, USA, 10106
Elevation Oncology Inc is an oncology company focused on the development of targeted therapeutics for the treatment of cancer in genomically defined patient populations. Its lead program is focused on neuregulin-1, or NRG1, fusions, which are rare genomic alterations that have the potential to be therapeutically actionable through targeted HER3 inhibition.
Executives
| Tammy Furlong |
officer: CHIEF FINANCIAL OFFICER |
C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
| Venbio Global Strategic Gp Iii, L.p. |
10 percent owner |
1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
| Venbio Global Strategic Fund Iii, L.p. |
10 percent owner |
1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
| Goodman Corey S |
10 percent owner |
1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
| Robert J Adelman |
10 percent owner |
1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158 |
| Aaron Royston |
10 percent owner |
200 CARDINAL WAY, 2ND FLOOR, REDWOOD CITY CA 94063 |
| David Dornan |
officer: Chief Scientific Officer |
C/O BOLT BIOTHERAPEUTICS, INC., 640 GALVESTON DRIVE, REDWOOD CITY CA 94063 |
| Valerie Malyvanh Jansen |
officer: Chief Medical Officer |
C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
| Cormorant Asset Management, Lp |
10 percent owner |
200 CLARENDON STREET, 52ND FLOOR, BOSTON MA 02116 |
| Andrew N Schiff |
other: Managing Member |
PLANET ZANETT INC, 135 E 57TH ST, NEW YORK NY 10022 |
| Steve Elms |
director, other: Managing Member |
888 SEVENTH AVE, 29TH FL, NEW YORK NY 10106 |
| Venbio Global Strategic Gp Iii, Ltd |
10 percent owner |
1700 OWENS STREET, SUITE 595, SAN FRANCISCI CA 94158 |
| Qiming U.s. Healthcare Gp Ii, Llc |
10 percent owner |
11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004 |
| Vertex Global Hc Fund Ii Pte. Ltd. |
10 percent owner |
250 NORTH BRIDGE ROAD, #11-01 RAFFLES CITY TOWER, SINGAPORE U0 179101 |
| Walsh Colin |
director |
C/O ELEVATION ONCOLOGY, INC., 888 SEVENTH AVENUE, 12TH FLOOR, NEW YORK NY 10106 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ELEV has been successfully added to your